Guenka Petrova

TL;DR: Most countries have put in place specific supply-side policies for promoting access to biosimilars, but investments should be made to clearly communicate on biosimilarars and educate stakeholders to support a sustainable biosimilar market.

TL;DR: Development of a pan-European definition of CAM use and CAM therapies are required to achieve surveys comparable between European countries, and more research investigating the efficacy and potential adverse effects of CAM therapies is needed because of increasing CAM use by children in Europe.

TL;DR: The primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective.

TL;DR: If MEAs are to improve access, countries should establish clear objectives for their implementation and a monitoring framework to measure their performance, as well as the burden of implementation.

TL;DR: Increasing use of EQ-5D is observed throughout CEE, but improvement in informed use and methodological quality of reporting is needed, and in jurisdictions where no national value set is available, in order to ensure comparability the authors recommend to apply the most frequently used UK tariff.